Literature DB >> 23206270

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.

Raija Silvennoinen, Veli Kairisto, Tarja-Terttu Pelliniemi, Mervi Putkonen, Pekka Anttila, Marjaana Säily, Anu Sikiö, Jorma Opas, Karri Penttilä, Taru Kuittinen, Tuomo Honkanen, Tuija Lundán, Vesa Juvonen, Tiina Luukkaala, Kari Remes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23206270     DOI： 10.1111/bjh.12139

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.

Authors:  Ola Landgren; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

2.  A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.

Authors:  R Silvennoinen; P Anttila; M Säily; T Lundan; J Heiskanen; T M Siitonen; S Kakko; M Putkonen; H Ollikainen; V Terävä; A Kutila; K Launonen; A Räsänen; A Sikiö; M Suominen; P Bazia; K Kananen; T Selander; T Kuittinen; K Remes; E Jantunen
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

3.  Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

Authors:  O Landgren; S Devlin; M Boulad; S Mailankody
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

Review 4.  Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation.

Authors:  Hiroyuki Takamatsu
Journal:  J Clin Med       Date:  2017-09-25       Impact factor: 4.241

5.  High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.

Authors:  Yago Nieto; Benigno C Valdez; Sai R Pingali; Roland Bassett; Ruby Delgado; John Nguyen; Nina Shah; Uday Popat; Roy B Jones; Borje S Andersson; Alison Gulbis; Sairah Ahmed; Qaiser Bashir; Simrit Parmar; Krina Patel; Alan Myers; Gabriela Rondon; Robert Z Orlowski; Richard Champlin; Muzaffar Qazilbash
Journal:  Lancet Haematol       Date:  2017-05-15       Impact factor: 18.959

6.  The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience.

Authors:  Amarilis Figueiredo; Rabih Kassis; Rashed Albacker; Arleigh McCurdy; Natasha Kekre; Harold Atkins
Journal:  Hematol Transfus Cell Ther       Date:  2019-06-14

7.  Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.

Authors:  R Silvennoinen; T Lundan; V Kairisto; T-T Pelliniemi; M Putkonen; P Anttila; V Huotari; P Mäntymaa; S Siitonen; L Uotila; T-L Penttilä; V Juvonen; T Selander; K Remes
Journal:  Blood Cancer J       Date:  2014-10-10       Impact factor: 11.037

8.  RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.

Authors:  Sini Luoma; Pekka Anttila; Marjaana Säily; Tuija Lundan; Jouni Heiskanen; Timo Siitonen; Sakari Kakko; Mervi Putkonen; Hanna Ollikainen; Venla Terävä; Marja Sankelo; Anu Partanen; Kirsi Launonen; Anu Räsänen; Anu Sikiö; Merja Suominen; Piotr Bazia; Kristiina Kananen; Juha Lievonen; Tuomas Selander; Tarja-Terttu Pelliniemi; Sorella Ilveskero; Virva Huotari; Pentti Mäntymaa; Anri Tienhaara; Esa Jantunen; Raija Silvennoinen
Journal:  Ann Hematol       Date:  2019-10-31       Impact factor: 3.673
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.